Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03701581 · ClinicalTrials.gov registry record · Phase 2
4-aminopyridine Treatment for Nerve Injury
A Phase 2 study of Prostate Cancer and Nerve Injury, sponsored by John Elfar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT03701581 is a Phase 2 study of Prostate Cancer and Nerve Injury that is actively recruiting participants, run by John Elfar. The registered enrollment target is 70 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03701581, a Phase 2 study of Prostate Cancer and Nerve Injury, is actively recruiting participants, sponsored by John Elfar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG 4-Aminopyridine
Study Locations (2)
Arizona
- University of Arizona - Tucson
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-06-05 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03701581
The ClinicalTrials.gov registry entry for NCT03701581 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The listed sponsor is John Elfar, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03701581 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT03701581 about?
NCT03701581 is a clinical study titled "4-aminopyridine Treatment for Nerve Injury". To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.
What is the current status of trial NCT03701581?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-06-05. Estimated completion is 2028-12.
What conditions does trial NCT03701581 study?
This clinical trial studies the following conditions: Prostate Cancer, Nerve Injury.
What interventions are being tested in trial NCT03701581?
The interventions under investigation include: Placebo (OTHER), 4-Aminopyridine (DRUG).
Who is sponsoring clinical trial NCT03701581?
This trial is sponsored by John Elfar, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03701581 being conducted?
This trial has 2 study locations across Arizona, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.